Abstract
Background Timely detection is crucial to improve outcomes in patients with cardiac amyloidosis (CA) by initiation of life-saving treatments. Although confirmatory bone scintigraphy is highly accurate for CA detection, identifying at-risk patients for referral remains challenging.
Objectives This study aimed to develop and validate a machine learning model, Amylo-Detect, using structured multimodal electronic health record (EHR) data to guide referrals for confirmatory scintigraphy and monoclonal protein testing.
Methods Consecutive all-comer patients (n=11,616) referred for bone scintigraphy at the Vienna General Hospital (2010-2023) were retrospectively included. Patients referred before August 2020 formed the development cohort. The remaining patients comprised the internal validation cohort. External validation was performed at the University Hospital Essen (n=1,521). Amylo-Detect was trained using 50 routinely available parameters to predict CA-suggestive uptake (Perugini grade ≥2) and compared with an existing score and clinical routine.
Results High-grade uptake was present in 388 patients (3.0%). Amylo-Detect demonstrated excellent performance in development (AUC 0.93), independent internal validation (AUC 0.91), and external validation cohort (AUC 0.91), outperforming existing scoring systems and clinical routine. Results were consistent across subgroups, even when crucial predictors were missing. Of the 42/388 (10.8%) patients missed in clinical routine, 12/42 (29%) were additionally detected by Amylo-Detect. The model further conveyed significant prognostic value for mortality and heart failure hospitalization.
Conclusions We present Amylo-Detect, a validated EHR-based tool for CA risk prediction, available as a web app, allowing application and further evaluation. By improving timely detection and referral, Amylo-Detect promises to address diagnostic delays and improve outcomes.
Author summary Cardiac amyloidosis is a progressive and often fatal heart disease that is frequently diagnosed too late, even though effective treatments are now available. A major challenge is recognizing which patients should be referred for specialized testing, because early symptoms are diverse and often non-specific. In this study, we developed and validated a machine learning prediction system, called Amylo-Detect, that uses routinely collected information from electronic health records to identify patients who may be at risk for cardiac amyloidosis. We trained and externally validated the tool using data from 13,137 patients across two hospitals. We found that Amylo-Detect was highly accurate in identifying patients with disease-indicative findings on confirmatory scans and identified a substantial number of patients who were not initially suspected of having cardiac amyloidosis. Amylo-Detect, which we make publicly available via a web app, consistently outperformed existing risk scores and routine clinical decision-making. Our findings suggest that automated analysis of electronic health records can support clinicians in recognizing cardiac amyloidosis earlier, reduce diagnostic delays, and potentially improve patient outcomes by enabling timely treatment.
Competing Interest Statement
CN reports speaker/consulting honoraria from Pfizer, Bayer, Prothena, and Boehringer Ingelheim and research contracts with Pfizer, AstraZeneca, the Austrian Society of Cardiology, the European Association of Cardiovascular Imaging, and the Austrian Science Fund. CPS received consulting and speaker fees from Pfizer. MH has received lecture fees from Siemens Healthineers and GE Healthcare. MH has received consulting fees from Evomics. TR has received honoraria, lecture fees, and grant support from Edwards Lifesciences, AstraZeneca, Bayer, Novartis, Berlin Chemie, Daiicho-Sankyo, Boehringer Ingelheim, Novo Nordisk, Cardiac Dimensions, and Pfizer. TR is co-founder of mycor GmbH, a company focusing on the development of ECG-algorithms for the identification of amyloidosis. The remaining authors have nothing to disclose.
Funding Statement
none
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medical University of Vienna's institutional review board gave ethical approval for this work (1557/2020). The requirement for informed consent was waived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
